DEABATE CA, MCIVOR RA, DI BARTOLO C, REGGIANI JL, SKUBA K, PIERCE PF; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 711 (abstract no. 177).
Med. Res. Ctr., New Orleans, LA
BACKGROUND: GAT, a new, broad-spectrum, 8-methoxy fluoroquinolone, has potent activity against respiratory pathogens associated with AECB. OBJECTIVES: To compare the clinical and bacteriologic efficacy and safety of GAT vs CEF in patients with AECB.METHODS: A multinational, randomized, double-blind, multicenter trial compared GAT (400 mg PO, QD) with CEF (250 mg PO, BID) given for 7-10 days. This analysis focused on the treatment of 211 North American AECB adult outpatients (88% with Type I exacerbation). Diagnosis was based on clinical signs/symptoms of AECB as well as a purulent sputum sample. Study design was in accordance with current IDSA and FDA guidelines.RESULTS: Among 166 clinically evaluable patients, clinical cure was 89% (76/85) for GAT vs 77% (62/81) for CEF (P = 0.01). A similar difference in efficacy rates was also observed whether the patients were smokers (96% [46/48] vs 81% [38/47]) or nonsmokers (81% [30/37] vs 71% [24/34]). In documented Streptococcus pneumoniae infections (n=17), clinical cure rates for GAT vs CEF were 100% (8/8) vs 44% (4/9), respectively, and microbiologic eradication was 100% (7/7) vs 38% (3/8), respectively. Clinical cure rates for GAT vs CEF in patients infected with Haemophilus influenzae were 100% (10/10) vs 69% (9/13), respectively. The most common adverse events for GAT and CEF were diarrhea (7% and 9%) and nausea (7% and 3%), respectively.CONCLUSION: In this population, oral GAT 400 mg once daily is safe, effective, and associated with a significantly higher rate of clinical cure than CEF in patients with AECB.
Publication Types:
Keywords:
- Adult
- Bronchitis, Chronic
- Cefuroxime
- Fluoroquinolones
- GAT
- Haemophilus Infections
- Haemophilus influenzae
- Humans
- Peptides
- cefuroxime axetil
- gatifloxacin
- therapy
Other ID:
UI: 102246473
From Meeting Abstracts